Italfarmaco Spa Patent-Cliff Exposure & CMS Drug Spending Portfolio

Italfarmaco Spa (US): 1 reconciled FDA prescription therapies, $25.2M 2024 CMS Part D & Medicaid spend, and $37,000 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2040-01-01
2024 CMS Total Public Spend$25.2M
2024 Medicare Part D Spend$2.0M
2024 Medicaid Spend$23.2M
California HCAI SB 17 FilingsSpecialty launch notice ($37,000 intro WAC)